Can biorelevant media be simplified by using SLS and Tween 80 to replace bile compounds?

Open Drug Delivery Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 30-37

  Taupitz, Thomas ^a   Klein, Sandra ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Biorelevant media; Dissolution; Poorly soluble drugs; Simplified media; Surfactants

Indexed keywords

DODECYL SULFATE SODIUM; POLYSORBATE 80; SURFACTANT; TAMOXIFEN CITRATE;

ARTICLE; BIOEQUIVALENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 77958610023     PISSN: None     EISSN: 18741266     Source Type: Journal    
DOI: 10.2174/1874126601004020030     Document Type: Article

References (15)

1. Galia, E.; Nicolaides, E.; Horter, D.; Lobenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res., 1998, 15(5), 698-705.
2. Nicolaides, E.; Galia, E.; Efthymiopoulos, C.; Dressman, J. B.; Reppas, C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data [In Process Citation]. Pharm. Res., 1999, 16(12), 1876-1882.
3. Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci., 2000, 11(Suppl 2), 73-80.
4. Kostewicz, E. S.; Brauns, U.; Becker, R.; Dressman, J. B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res., 2002, 19(3), 345-349.
5. Nicolaides, E.; Hempenstall, J.; Reppas, C. Biorelevant dissolution tests with flow-through apparatus. Dissolution Technol., 2000, 7(1), 8-11.
6. Nicolaides, E.; Symillides, M.; Dressman, J. B.; Reppas, C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res., 2001, 18(3), 380-388.
7. Zoeller, T.; Klein, S. Simplified biorelevant media for screening dissolution performance of poorly soluble. Drugs Dissolution Technol., 2007, 14(4), 8-13.
8. EMEA, Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products - Human Medicines Evaluation Unit: London, 2000.
9. USP 32; United States Pharmacopoeia Convention, Inc.: Rockville MD, 2009.
10. FDA, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Rockville MD, USA, 1997.
11. FDA, FDA-Recommended Dissolution Methods Database. In CDER. http://www.accessdata.fda.gov/scripts/cder/dissolution [accessed October 22, 2009].
12. Buchanan, C. M.; Buchanan, N. L.; Edgar, K. J.; Lambert, J. L.; Posey-Dowty, J. D.; Ramsey, M. G.; Wempe, M. F., Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes. J. Pharm. Sci. 2006, 95(10), 2246-2255.
13. Buchanan, C. M.; Buchanan, N. L.; Edgar, K. J.; Little, J. L.; Malcolm, M. O.; Ruble, K. M.; Wacher, V. J.; Wempe, M. F. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta-cyclodextrin formulations. J. Pharm. Sci., 2007, 96(3), 644-660.
14. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res., 2005, 22(1), 11-23.
15. WHO Working document QAS/04.109/Rev. 1. Proposal to waive in vivo bioequivalence requirements for the WHO model list of Essential medicines immediate release, solid oral dosage forms. In Working Document. World Health Organisation: Geneva, 2005.